[go: up one dir, main page]

ES2116290T3 - 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios. - Google Patents

2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.

Info

Publication number
ES2116290T3
ES2116290T3 ES91907515T ES91907515T ES2116290T3 ES 2116290 T3 ES2116290 T3 ES 2116290T3 ES 91907515 T ES91907515 T ES 91907515T ES 91907515 T ES91907515 T ES 91907515T ES 2116290 T3 ES2116290 T3 ES 2116290T3
Authority
ES
Spain
Prior art keywords
substituted
arylalkyl
alkyl
inflammatory agents
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907515T
Other languages
English (en)
Inventor
Gary C M Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2116290T3 publication Critical patent/ES2116290T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) EN LA QUE R ES ALQUIL, ARALQUIL O ARILALQUIL SUBSTITUIDO, O ALQUENIL QUE CONTIENE UNO O MAS ENLACES OLEFINICOS; X ES O, NH O NR1, DONDE R1 ES ALQUIL DE ENTRE 1 Y 20 ATOMOS DE CARBONO O ARALQUIL; E Y ES H, ALQUIL DE ENTRE 1 Y 20 ATOMOS DE CARBONO, ARALQUIL, ARIL, ARIL SUBSTITUIDO, ARILALQUIL SUBSTITUIDO, ALQUENIL CONTENIENDO UNO O MAS ENLACES OLEFINICOS, PO(0H)2, PO(OH)OR2, PO(OH)R2, PO(OR2)2, DONDE R2 ES INDEPENDIENTEMENTE ALQUIL DE ENTRE 1 Y 20N ATOMOS DE CARBONO, FENIL O FENIL SUBSTITUIDO, ADEMAS Y ES CO-R3, CO-OR3, CONHR3, SO2R3, SO2NHR3, (CH2)-O-R3, O (CH2)N-O-(CH2)M-OR3, DONDE N, Y M, SON ENTEROS Y VALEN INDEPENDIENTEMENTE ENTRE 1 Y 20 Y R3 ES H, ALQUIL, ALQUENIL CONTENIENDO UNO O MAS ENLACES OLEFINICOS, ARIL, ARIL SUBSTITUIDO, ARILALQUIL O ARILALQUIL SUBSTITUIDO, CON LA CONDICION DE QUE CUANDO Y SEA CO-R3, CO-OR3 Y CONHR3, ENTONCES R3 NO SERA HIDROGENO. LOS COMPUESTOS SON ANTAGONISTAS DEL CANAL CA2+, TIENEN POCA O NINGUNA ACTIVIDAD COMO INHIBIDORES DE LA FOSFOLIPASA A2, Y SON AGENTES ANTIINFLAMATORIOS.
ES91907515T 1990-04-17 1991-03-25 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios. Expired - Lifetime ES2116290T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/510,367 US5043457A (en) 1990-04-17 1990-04-17 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ES2116290T3 true ES2116290T3 (es) 1998-07-16

Family

ID=24030459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907515T Expired - Lifetime ES2116290T3 (es) 1990-04-17 1991-03-25 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.

Country Status (9)

Country Link
US (1) US5043457A (es)
EP (1) EP0525002B1 (es)
JP (1) JPH05506024A (es)
AT (1) ATE165972T1 (es)
CA (1) CA2078770A1 (es)
DE (1) DE69129408T2 (es)
ES (1) ES2116290T3 (es)
IE (1) IE911266A1 (es)
WO (1) WO1991016048A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
DE60326482D1 (de) * 2002-10-10 2009-04-16 Merck & Co Inc Testverfahren für zustandsabhängige calciumkanal-agonisten/-antagonisten
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US4447455A (en) * 1980-12-01 1984-05-08 Madaus And Company Oral urolithiasis remedy
US4616089A (en) * 1983-08-03 1986-10-07 University Of California Synthetic anti-inflammatory derivatives of manoalide
DE3472958D1 (en) * 1983-08-03 1988-09-01 Univ California Synthetic analgesic and/or anti-inflammatory derivatives of manoalide
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
US4789749A (en) * 1984-06-18 1988-12-06 The Regents Of The University Of California Manoalide analogs
ZA864674B (en) * 1985-07-01 1988-02-24 Lilly Co Eli Furanone derivatives
US4786651A (en) * 1986-02-03 1988-11-22 Allergan, Inc. Treatment of cutaneous hyperproliferative dermatoses with manoalide
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
CA1329390C (en) * 1987-06-08 1994-05-10 John N. Bonfiglio Anti-inflammatory furanones
US4916241A (en) * 1988-06-06 1990-04-10 American Home Products Corporation Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
US4935530A (en) * 1988-10-18 1990-06-19 Allergan, Inc. Process for preparing 5-substituted-3-furaldehydes
US4957917A (en) * 1989-10-25 1990-09-18 Allergan, Inc. Anti-inflammatory furanones
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents

Also Published As

Publication number Publication date
EP0525002A4 (en) 1993-03-10
EP0525002B1 (en) 1998-05-13
DE69129408D1 (de) 1998-06-18
JPH05506024A (ja) 1993-09-02
CA2078770A1 (en) 1991-10-18
DE69129408T2 (de) 1998-09-03
EP0525002A1 (en) 1993-02-03
WO1991016048A1 (en) 1991-10-31
IE911266A1 (en) 1991-10-23
ATE165972T1 (de) 1998-05-15
US5043457A (en) 1991-08-27

Similar Documents

Publication Publication Date Title
ES2116290T3 (es) 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
ES477695A1 (es) Un procedimiento para preparar derivados de deshidrociclici-minoacidos.
ATE69817T1 (de) Tetraoxodiazabicyclo-(3,3,1)-nonane.
NZ195992A (en) 5-halopyrimidines;their 2-sulphides and s-oxides;pharmaceutical compositions
ES465384A1 (es) Procedimiento para la obtencion de ciclopentan-1-aminas
ES488788A0 (es) Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa.
SE7601143L (sv) Nytt oxadiazolinonderivat
DE3875346D1 (de) Zusammensetzungen, die mit 1-oxo- oder thiokohlenwassserstoff substituierte azacycloalkane enthalten.
AU541413B2 (en) 2-(1,4-benzodioxan-2-ylalicyl)imidazoles
ES545575A0 (es) Un procedimiento para la preparacion de tiazolidinas
ES2070623T3 (es) Oxisulfonilureas inhibidoras de acat.
ES477785A1 (es) Procedimiento para la preparacion de nuevas 2-fenilimino- imidazolidinas sustituidas.
ES467069A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1-3-bencenodimetanol
ES481551A1 (es) Procedimiento de preparacion de nuevos compuestos bis (ari- loxicarboxilicos).
ES477803A1 (es) Procedimiento para la obtencion de compuestos de fenilaceta-mida.
DK524283A (da) Fremgangsmaade til fremstilling af nitrosoureaderivater
FI823458A0 (fi) Substituerade tiazolidinylestrar av mineralsyror
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
ES8504180A1 (es) Procedimiento para preparar nuevos derivados de piperidina
ES8401456A1 (es) Procedimiento para la preparacion de 2-aminometilfenoles.
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
FI852036L (fi) Foerfarande foer framstaellning av nya resorcinetrar.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525002

Country of ref document: ES